Pelage Pharmaceuticals Announces First Patient Dosed in Phase 2/3 AWAKEN Trial of PP405 for Androgenetic Alopecia, the Most Common Form of Hair Loss
For best results when printing this announcement, please click on link below: Pelage Pharmaceuticals Announces First Patient Dosed in Phase 2/3 AWAKEN Trial of PP405 for Androgenetic Alopecia, the Most Common Form of Hair Loss AWAKEN will evaluate the efficacy and long-term safety of PP405, a first-in-class topical the